These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 10547423

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
    McVernon J, Nolan T, Richmond P, Reynolds G, Nissen M, Lambert SB, Marshall H, Papa T, Rehm C.
    Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
    van Ravenhorst MB, van der Klis FRM, van Rooijen DM, Knol MJ, Stoof SP, Sanders EAM, Berbers GAM.
    Vaccine; 2017 Aug 24; 35(36):4745-4752. PubMed ID: 28668575
    [Abstract] [Full Text] [Related]

  • 11. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12-18 months of age.
    Habermehl P, Leroux-Roels G, Sänger R, Mächler G, Boutriau D.
    Hum Vaccin; 2010 Aug 24; 6(8):640-51. PubMed ID: 20697200
    [Abstract] [Full Text] [Related]

  • 12. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.
    Marchant CD, Miller JM, Marshall GS, Blatter M, Aris E, Friedland LR, Boutriau D, HibMenCY-TT 005 Study Group.
    Pediatr Infect Dis J; 2010 Jan 24; 29(1):48-52. PubMed ID: 20035207
    [Abstract] [Full Text] [Related]

  • 13. Murine immune responses to Neisseria meningitidis group C capsular polysaccharide and a thymus-dependent toxoid conjugate vaccine.
    Rubinstein LJ, García-Ojeda PA, Michon F, Jennings HJ, Stein KE.
    Infect Immun; 1998 Nov 24; 66(11):5450-6. PubMed ID: 9784556
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
    Klein NP, Habanec T, Kosina P, Shah NR, Kolhe D, Miller JM, Hezareh M, Van der Wielen M.
    Vaccine; 2018 Apr 19; 36(17):2356-2363. PubMed ID: 29576307
    [Abstract] [Full Text] [Related]

  • 15. Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys.
    Devi SJ, Zollinger WD, Snoy PJ, Tai JY, Costantini P, Norelli F, Rappuoli R, Frasch CE.
    Infect Immun; 1997 Mar 19; 65(3):1045-52. PubMed ID: 9038314
    [Abstract] [Full Text] [Related]

  • 16. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults.
    Anderson EL, Bowers T, Mink CM, Kennedy DJ, Belshe RB, Harakeh H, Pais L, Holder P, Carlone GM.
    Infect Immun; 1994 Aug 19; 62(8):3391-5. PubMed ID: 8039909
    [Abstract] [Full Text] [Related]

  • 17. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
    Dbaibo G, Van der Wielen M, Reda M, Medlej F, Tabet C, Boutriau D, Sumbul A, Anis S, Miller JM.
    Int J Infect Dis; 2012 Aug 19; 16(8):e608-15. PubMed ID: 22704725
    [Abstract] [Full Text] [Related]

  • 18. Safety and immunogenicity of a Haemophilus influenzae type B polysaccharide-tetanus toxoid conjugate vaccine combined with diphtheria, tetanus and pertussis vaccines in Thai infants.
    Chotpitayasunondh T, Panpitpat C, Thisyakorn U, Furer E, Que JU, Hasler T, Cryz SJ.
    Southeast Asian J Trop Med Public Health; 1997 Mar 19; 28(1):91-8. PubMed ID: 9322290
    [Abstract] [Full Text] [Related]

  • 19. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.
    Vesikari T, Forstén A, Desole MG, Ferrera G, Caubet M, Mesaros N, Boutriau D.
    Pediatr Infect Dis J; 2013 May 19; 32(5):521-9. PubMed ID: 23190785
    [Abstract] [Full Text] [Related]

  • 20. Immunoglobulin G subclass response to a meningococcal quadrivalent polysaccharide-diphtheria toxoid conjugate vaccine.
    Findlow H, Southern J, Mabey L, Balmer P, Heyderman RS, Auckland C, Morris R, Miller E, Borrow R.
    Clin Vaccine Immunol; 2006 Apr 19; 13(4):507-10. PubMed ID: 16603620
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.